DiabesityNCT07247409
Establishment of Hong Kong Diabesity Register
An observational study of Diabesity, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
All participants of the Diabesity Register will receive structured assessment by nurses guided by the JADE portal at baseline including eye, feet, blood and urine examination with evaluation of BMI, blood pressure, HbA1c, lipid profile, renal and liver function tests, urine for albumin-creatinine ratio. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Diabesity
- How many people
- 800 participants
- Where
- 1 siteHong Kong
- Study dates
- 22 Oct 2025to 31 Dec 2029
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Study population: All study subjects will be recruited from the Diabetes Mellitus and Endocrine Centre (DMEC) at PWH. Since 1995, the PWH runs a comprehensive complication screening program as part of a quality improvement program in the DMEC. On a weekly basis, patients with diabetes mellitus undergo comprehensive assessments for risk factors and complications by nurses and health care assistants using standard protocols.
Who may be able to join
- Type 2 diabetes;
- Obesity reaching action level as defined as body mass index (BMI) 27.5 kg/m2 and/or waist circumference (WC) 80cm in women and 90cm in men;
- Age between 18 and 50 years;
- Able to conversate with smartphone technology and web-based program.
- Able to read Chinese and communicate using Chinese.
Who cannot join
- Type 1 diabetes;
- Active malignant disease including those with history of malignant disease less than 5 years of disease-free duration;
- Life expectancy less than 12 months;
- Any medical illness or condition as judged by the investigators as ineligible to participate the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
Hong Kong
Alice Pik Shan Kong, MD, +852 3505 2648, alicekong@cuhk.edu.hk
About this study
All participants of the Diabesity Register will receive structured assessment by nurses guided by the JADE portal at baseline including eye, feet, blood and urine examination with evaluation of BMI, blood pressure, HbA1c, lipid profile, renal and liver function tests, urine for albumin-creatinine ratio. All patients will return at 3-year for a repeat assessment of physical and psychological health, as well as changes over time.
- Conditions
- Diabesity
- Being tested
- No Intervention: Observational Cohort
- Medical subject headings
- Diabesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
It is an registry so no intervention will be used.
| Study group | Role | What they receive |
|---|---|---|
| Diabesity | People with diabetes and obesity Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
A composite of incidence
Incidence of diabetes-related complications
Measured: 3 years
Secondary outcomes (6)
Incidence of diabetic mellitus retinopathy
Measured: 3 years
Incidence of diabetic mellitus nephropathy
Measured: 3 years
Incidence of diabetic mellitus neuropathy
Measured: 3 years
Incidence of myocardial infarction
Measured: 3 years
Incidence of stroke
Measured: 3 years
Incidence of peripheral artery disease
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2025
- Study start22 Oct 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabesityStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 800 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alice Pik Shan KONG, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07247409
- Sponsor's protocol ID
- CRE 2025.324 register
- Status last verified
- Oct 2025
- First submitted
- 18 Nov 2025
- Last updated
- 25 Nov 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishment of Hong Kong Diabesity Register
- ClinicalTrials.gov ID
- NCT07247409
- Acronym / sponsor ID
- CRE 2025.324 register
- Conditions
- Diabesity
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 22 Oct 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 25 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
All participants of the Diabesity Register will receive structured assessment by nurses guided by the JADE portal at baseline including eye, feet, blood and urine examination with evaluation of BMI, blood pressure, HbA1c, lipid profile, renal and liver function tests, urine for albumin-creatinine ratio. All patients will return at 3-year for a repeat assessment of physical and psychological health, as well as changes over time.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Diabesity | – | Other: No Intervention: Observational CohortPeople with diabetes and obesity |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- All study subjects will be recruited from the Diabetes Mellitus and Endocrine Centre (DMEC) at PWH. Since 1995, the PWH runs a comprehensive complication screening program as part of a quality improvement program in the DMEC. On a weekly basis, patients with diabetes mellitus undergo comprehensive assessments for risk factors and complications by nurses and health care assistants using standard protocols.
Key inclusion criteria (5 listed)
- Type 2 diabetes;
- Obesity reaching action level as defined as body mass index (BMI) 27.5 kg/m2 and/or waist circumference (WC) 80cm in women and 90cm in men;
- Age between 18 and 50 years;
- Able to conversate with smartphone technology and web-based program.
- Able to read Chinese and communicate using Chinese.
Key exclusion criteria (4 listed)
- Type 1 diabetes;
- Active malignant disease including those with history of malignant disease less than 5 years of disease-free duration;
- Life expectancy less than 12 months;
- Any medical illness or condition as judged by the investigators as ineligible to participate the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortIt is an registry so no intervention will be used. | Other | Diabesity |
Primary outcome
A composite of incidence
Time frame: 3 years
Incidence of diabetes-related complications
6 secondary outcomes
Incidence of diabetic mellitus retinopathy
Time frame: 3 years
Incidence of diabetic mellitus nephropathy
Time frame: 3 years
Incidence of diabetic mellitus neuropathy
Time frame: 3 years
Incidence of myocardial infarction
Time frame: 3 years
Incidence of stroke
Time frame: 3 years
Incidence of peripheral artery disease
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2025.
Related trials for Diabesity
Recruiting
Endoscopic Sleeve Gastroplasty Plus Duodenal pulsENDO for Obese T2DM
Obesity Type 2 Diabetes Mellitus
Recruiting
Hong Kong Diabesity Register & 3-Year Trial on Integrated Care for Chinese With Diabesity
Diabesity
RecruitingObservational study
Taiwan Diabesity Study:Comparison With Mild Obese T2DM Patients Who Under Metabolic Surgery
Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabesity, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alice Pik Shan Kong, MD (+852 3505 2648, alicekong@cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
A composite of incidence (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2025.